TABLE 3.
TTO and WSP analysis of different groups.
| Drug | TTO (days) | Weibull distribution | | ||
|---|---|---|---|---|---|
| Case reports | Median(d) (IQR) |
Scale parameter α (95%CI) |
Shape parameter Β (95%CI) |
Type | |
| Trastuzumab +Lapatinib |
386 | 41.5 (3–352.5) | 203.18 (156.28–250.08) | 0.488 (0.447–0.528) | Early failure |
| Trastuzumab +Neratinib |
59 | 92 (27–721) | 304.67 (171.96–437.39) | 0.634 (0.500–0.768) | Early failure |
| Trastuzumab +Tucatinib |
503 | 42 (14–123) | 114.26 (96.37–132.16) | 0.614 (0.574–0.655) | Early failure |
| Trastuzumab | 11,499 | 26 (4–147) | 122.51 (117.98–127.04) | 0.579 (0.570–0.588) | Early failure |